| |
| | Patent 5242909: Method of using 4-(2-(P-((E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl) propenyl)phenoxy)ethyl)morpholine with cytostatics |
 | | Therapy with cytostatic agents is frequently associated with undesirable effects which have their origin in the toxicity of the cytostatic agent. |
 | | The dosing in an individual case must be fitted to the requirements of the patient and to the other cytostatic or BRM used in parallel, which lies in the purview of the specialist knowledge. |
 | | The invention is also concerned with a commercial pack containing as the pharmaceutically active substance 4-[2-[p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl ]phenoxy]ethyl]morpholine together with instructions for its use in combination with a cytostatic agent for the simultaneous, separate or sequential use in cancer prophylaxis or therapy particularly for cancers which are sensitive to such a combination. |
| www.freepatentsonline.com /5242909.html |
|